Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Altimmune, Inc. (NASDAQ:ALT) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $15.7143.

A number of research analysts have issued reports on the stock. Leerink Partners began coverage on shares of Altimmune in a report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 target price for the company. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, June 24th. Truist Financial began coverage on Altimmune in a research note on Wednesday, March 18th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Wall Street Zen raised Altimmune from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th.

Altimmune Price Performance

Shares of NASDAQ:ALT traded down $0.07 on Friday, reaching $3.05. 2,986,213 shares of the company were exchanged, compared to its average volume of 4,630,043. The company has a 50-day moving average of $2.91 and a 200-day moving average of $3.60. The company has a current ratio of 29.56, a quick ratio of 29.56 and a debt-to-equity ratio of 0.12. The firm has a market cap of $593.13 million, a price-to-earnings ratio of -3.28 and a beta of 0.25. Altimmune has a 1-year low of $2.56 and a 1-year high of $6.44.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. Equities analysts forecast that Altimmune will post -0.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. raised its stake in Altimmune by 27.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after purchasing an additional 1,928 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Altimmune by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after buying an additional 2,241 shares during the last quarter. Concurrent Investment Advisors LLC raised its position in shares of Altimmune by 10.4% in the fourth quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock valued at $96,000 after buying an additional 2,500 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Altimmune by 10.9% during the second quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after buying an additional 2,748 shares during the period. Finally, Deutsche Bank AG lifted its stake in shares of Altimmune by 4.0% during the fourth quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock valued at $289,000 after buying an additional 3,047 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.